Company profile: Inanovate
1.1 - Company Overview
Company description
- Provider of multiplexed protein quantification and longitudinal assay screening technologies for detecting and measuring multiple proteins, including the Bio-ID real-time platform (high sensitivity confocal imaging and microfluidics) and LAS time-resolved fluorescent assays. Also offers a breast cancer blood test to improve mammography accuracy and detect recurrence, Bio-ID services, an alliance program for LAS assays, and the i-Slide protein microarray substrate.
Products and services
- Longitudinal Assay Screening (LAS): Time-resolved technology that detects and measures multiple proteins by taking fluorescent measurements of protein interactions
- Bio-ID: Microfluidic-enabled multiplexed protein quantification platform that measures protein concentrations in real-time using high-sensitivity confocal imaging
- Breast Cancer Diagnostics: Biomarker-based blood test that improves the accuracy of mammography and detects recurrence by combining the Bio-ID platform with specific biomarkers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Inanovate
Exelixis
HQ: United States
Website
- Description: Provider of therapies for cancer and other serious diseases, discovering, developing and commercializing small-molecule and biotherapeutic treatments. Marketed products include CABOMETYX (cabozantinib) and COTELLIC (cobimetinib); MINNEBRO (esaxerenone) is marketed in Japan by Daiichi Sankyo. Offers clinical trials, early access to investigational medicines, and collaborations to advance experimental molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exelixis company profile →
Myriad Genetics
HQ: United States
Website
- Description: Provider of genetic testing and molecular profiling solutions, including hereditary cancer risk assessment (MyRisk), pharmacogenomic testing for mental health medications (GeneSight), prostate cancer aggressiveness evaluation (Prolaris), tumor genomic profiling (Precise), carrier screening (Foresight), and non-invasive prenatal screening (Prequel).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myriad Genetics company profile →
X4 Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral small molecule CXCR4 antagonists, including mavorixafor to mobilize white blood cells and improve immune function in patients with WHIM syndrome and certain chronic neutropenic disorders; runs a global Phase 3 WHIM trial with positive results and awaiting FDA approval, plus a Phase 2 trial in chronic neutropenic disorders with plans for Phase 3.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X4 Pharmaceuticals company profile →
Siren Biotechnology
HQ: United States
Website
- Description: Provider of AAV immuno-gene therapies that combine AAV gene therapy and cytokine immunotherapy into a single modality for solid tumors, including brain and eye cancers. Its approach delivers engineered cytokines directly to tumors to activate immune responses and destroy cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Siren Biotechnology company profile →
Kudos Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development based on the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kudos Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Inanovate
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Inanovate
2.2 - Growth funds investing in similar companies to Inanovate
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Inanovate
4.2 - Public trading comparable groups for Inanovate
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →